It seems….based on this article …that Msb has just travelled the hard path of broken glass in order to simplify the pathway for other gene and cell therapies. Hopefully the end result will be a win-win for the medical community with the benefit focus on patients and their families. However, ultimately it could mean that our competitors could be effectively snapping at our heels with certain inflammatory conditions having derived benefit from a simplified approval pathway.
It seems….based on this article …that Msb has just travelled the...
-
- There are more pages in this discussion • 300 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.04 |
Change
-0.030(2.80%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.05 | $1.04 | $647.4K | 622.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 93140 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 36852 | 8 |
View Market Depth
| Last trade - 10.09am 30/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |